Jacopo P.
- Country
- Italy
- Department
- UOC Oncologia 2
Research Overview
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Neoadjuvant Immunotherapy with Nivolumab, Ipilimumab, MDNA11, and Tocilizumab in High-Risk Resectable Melanoma: A Phase Ib Multicentre Randomised Trial
- Evaluation of Pembrolizumab, Quavonlimab, and Lenvatinib in Advanced Melanoma with Brain Metastases: A Phase 1/2 Open-Label Study
Data & Insights
Has run more than one trial at 161 of 288 partner sites.
Specializations
Advanced Melanoma Treatment
The investigator specializes in treating advanced and metastatic melanoma, focusing on various therapeutic approaches including immunotherapy combinations and novel treatment strategies for previously untreated cases.
- First-line therapy development
- Combination immunotherapy assessment
- Treatment resistance management
Specialized Melanoma Variants
Demonstrates expertise in treating distinct melanoma subtypes, including uveal melanoma and Merkel cell carcinoma. Focuses on developing targeted approaches for these specific conditions.
- Ocular/uveal melanoma treatment
- Surgical and medical management
- Novel therapeutic combinations
Adjuvant Therapy Development
Conducts research in post-operative adjuvant therapy for various stages of melanoma, with particular attention to high-risk resected cases and preventive treatment strategies.
- Stage II-IV melanoma management
- Recurrence prevention protocols
- Risk-stratified treatment approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.